Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

In a challenging market environment, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached its 52-week low, trading at $22 ...

Two Nebraska researchers have launched a startup company aimed at bringing to market an innovative method for delivering therapeutics, gene editing tools, plasmids and more to targeted locations in ...

The New Drug Application for TAR-200 is supported by results from the Phase IIb SunRISe-1 study, which demonstrated an 83.5% ...

The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

The Birmingham Biotechnology Hub, which is led by Southern Research, will receive funding to use artificial intelligence to shorten drug development to provide ... said in a statement this morning.

VisiRose Inc. (”VisiRose” or the “Company”), a privately-held, clinical-stage biotechnology company developing novel ocular ...

Chase Malackowski was diagnosed with Ewing's Sarcoma at eight years old. After trialing a "single patient Investigational New ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

The investigational new drug application for the nanoparticle drug SNB-101 has been cleared for small cell lung cancer ...

In its latest attempt to bulk up its cancer drug portfolio, AbbVie has signed a new licensing agreement with China-based Simcere Zaiming to develop a treatment for myeloma, a type of blood cancer, in ...